Author: Steve Kopczak

LitAlert ~~ GeneLit.com

    • A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors.
    • Gao B, Voskoboynik M, Cooper A, Wilkinson K, Hoon S, Hsieh CY, Cai S, Tian YE, Bao J, Ma N, Wang C, Zhang M, Li B, Guo M, Zhou R, Wang X, Xu C, de Souza P.
    • Cancer. 2023 Jan 31. doi: 10.1002/cncr.34662. Epub ahead of print.

    Related:

    •• Identifier: NCT03507543: The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors. (ClinicalTrials.gov . Accessed 2023 Jan 31.)

    • Response to Ovarian Stimulation for Urgent Fertility Preservation before Gonadotoxic Treatment in BRCA-Pathogenic-Variant-Positive Breast Cancer Patients.
    • El Moujahed L, Philis R, Grynberg M, Laot L, Mur P, Amsellem N, Mayeur A, Benoit A, Rakrouki S, Sifer C, Peigné M, Sonigo C.
    • Cancers (Basel). 2023 Jan 31;15(3):895. doi: 10.3390/cancers15030895.

    • Germline Testing in Prostate Cancer: Implementation and Disparities of Care.
    • Brown LC, Armstrong AJ.
    • JCO Oncol Pract. 2023 Jan 31:OP2200804. doi: 10.1200/OP.22.00804. Epub ahead of print.

    • Dr. King on Delays in Access to Germline Testing in Pancreatic Cancer.
    • King D.
    • OncLive. OncLive TV. 2023 Jan 31.

    • Evaluation of inherited germline mutations in cancer susceptibility genes among pancreatic cancer patients: a single-center study.
    • Tavano F, Gioffreda D, Fontana A, Palmieri O, Gentile A, Latiano T, Latiano A, Latiano TP, Scaramuzzi M, Maiello E, Bazzocchi F, Perri F.
    • Mol Med. 2023 Jan 30;29(1):14. doi: 10.1186/s10020-023-00600-1.

    • Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer.
    • Penson RT, Ambrosio AJ, Whalen CA, Krasner CN, Konstantinopoulos PA, Bradley C, Matulonis UA, Birrer MJ.
    • Oncologist. 2023 Jan 30:oyac275. doi: 10.1093/oncolo/oyac275. Epub ahead of print.

    Related:

    •• Identifier: NCT01033123: A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer. (ClinicalTrials.gov . Accessed 2023 Jan 31.)

    •• Identifier: NCT01033292: A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer. (ClinicalTrials.gov . Accessed 2023 Jan 31.)

    • Variations in Practice and Geographic Disparities Between Dedicated Multidisciplinary Clinics for BRCA1/BRCA2 Mutation Carriers in Israel.
    • Hermann N, Mor P, Kaidar-Person O, Bernstein-Molho R, Brodsky M, Madorsky Feldman D, Flugelman AA, Aboody Nevo H, Meshoulam Avital D, Sklair-Levy M, Friedman E, Allweis TM.
    • Isr Med Assoc J. 2023 Jan;25(1):18-22.

    • LitAlert ~~ GeneLit.com

    • Characteristics of familial pancreatic cancer families with additional colorectal carcinoma.
    • Lehman B, Matthäi E, Gercke N, Denzer UW, Figiel J, Hess T, Slater EP, Bartsch DK.
    • Fam Cancer. 2023 Jan 31. doi: 10.1007/s10689-023-00328-1. Epub ahead of print.

    • The Use of Instagram by Gynecologic Oncology Providers as a Patient Education Tool for Patients at High-Risk of Gynecologic Cancer.
    • Holtzman S, Carr C, Zeligs K, Blank SV.
    • Gynecol Oncol Rep. 2023 Jan 31;101143. doi: 10.1016/j.gore.2023.101143.

    • Long-term effects of premenopausal risk-reducing salpingo-oophorectomy on cognition in women with high familial risk of ovarian cancer: A cross-sectional study.
    • Terra L, Lee Meeuw Kjoe PR, Agelink Van Rentergem JA, Beekman MJ, Heemskerk-Gerritsen BAM, Van Beurden M, Roeters Van Lennep JE, Van Doorn HC, De Hullu JA, Mourits MJE, Van Dorst EBL, Mom CH, Slangen BFM, Gaarenstroom KN, van der Kolk LE, Collée JM, Wevers MR, Ausems MGEM, Van Engelen K, Van De Beek I, Berger LPV, Van Asperen CJ, Gomez Garcia EB, Maas AHEM, Hooning MJ, Van Der Wall E, Van Leeuwen FE, Schagen SB.
    • BJOG. 2023 Jan 30. doi: 10.1111/1471-0528.17415. Epub ahead of print.

    • Integrative Analysis of Germline Rare Variants in Clear and Non-Clear Cell Renal Cell Carcinoma.
    • Han S, Camp SY, Chu H, Collins R, Gillani R, Park J, Bakouny Z, Ricker CA, Reardon B, Moore N, Kofman E, Labaki C, Braun D, Choueiri TK, AlDubayan SH, Van Allen EM.
    • medRxiv [Preprint]. 2023 Jan 19:2023.01.18.23284664. doi: 10.1101/2023.01.18.23284664.

    • Estimating clinical risk in gene regions from population sequencing cohort data.
    • Fife JD, Cassa CA.
    • medRxiv [Preprint]. 2023 Jan 9:2023.01.06.23284281. doi: 10.1101/2023.01.06.23284281.

    • Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
    • Pujade-Lauraine E, Brown J, Barnicle A, Wessen J, Lao-Sirieix P, Criscione SW, du Bois A, Lorusso D, Romero I, Petru E, Yoshida H, Vergote I, Colombo N, Hietanen S, Provansal M, Schmalfeldt B, Pignata S, Martín Lorente C, Berton D, Runnebaum IB, Ray-Coquard I.
    • JCO Precis Oncol. 2023 Jan;7:e2200258. doi: 10.1200/PO.22.00258.

    Related:

    •• Identifier: NCT02477644: Platine, Avastin and OLAparib in 1st Line (PAOLA-1). (ClinicalTrials.gov . Accessed 2023 Jan 30.)

    • Integrative Analysis of Germline Rare Variants in Clear and Non-Clear Cell Renal Cell Carcinoma.
    • Han S, Camp SY, Chu H, Collins R, Gillani R, Park J, Bakouny Z, Ricker CA, Reardon B, Moore N, Kofman E, Labaki C, Braun D, Choueiri TK, AlDubayan SH, Van Allen EM.
    • medRxiv [Preprint]. 2023 Jan 19:2023.01.18.23284664. doi: 10.1101/2023.01.18.23284664.

    • Integrative Analysis of Germline Rare Variants in Clear and Non-Clear Cell Renal Cell Carcinoma.
    • Han S, Camp SY, Chu H, Collins R, Gillani R, Park J, Bakouny Z, Ricker CA, Reardon B, Moore N, Kofman E, Labaki C, Braun D, Choueiri TK, AlDubayan SH, Van Allen EM.
    • medRxiv [Preprint]. 2023 Jan 19:2023.01.18.23284664. doi: 10.1101/2023.01.18.23284664.

    • Long-term effects of premenopausal risk-reducing salpingo-oophorectomy on cognition in women with high familial risk of ovarian cancer: A cross-sectional study.
    • Terra L, Lee Meeuw Kjoe PR, Agelink Van Rentergem JA, Beekman MJ, Heemskerk-Gerritsen BAM, Van Beurden M, Roeters Van Lennep JE, Van Doorn HC, De Hullu JA, Mourits MJE, Van Dorst EBL, Mom CH, Slangen BFM, Gaarenstroom KN, van der Kolk LE, Collée JM, Wevers MR, Ausems MGEM, Van Engelen K, Van De Beek I, Berger LPV, Van Asperen CJ, Gomez Garcia EB, Maas AHEM, Hooning MJ, Van Der Wall E, Van Leeuwen FE, Schagen SB.
    • BJOG. 2023 Jan 30. doi: 10.1111/1471-0528.17415. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • The Use of Instagram by Gynecologic Oncology Providers as a Patient Education Tool for Patients at High-Risk of Gynecologic Cancer.
    • Holtzman S, Carr C, Zeligs K, Blank SV.
    • Gynecol Oncol Rep. 2023 Jan 31;101143. doi: 10.1016/j.gore.2023.101143.

    • Long-term effects of premenopausal risk-reducing salpingo-oophorectomy on cognition in women with high familial risk of ovarian cancer: A cross-sectional study.
    • Terra L, Lee Meeuw Kjoe PR, Agelink Van Rentergem JA, Beekman MJ, Heemskerk-Gerritsen BAM, Van Beurden M, Roeters Van Lennep JE, Van Doorn HC, De Hullu JA, Mourits MJE, Van Dorst EBL, Mom CH, Slangen BFM, Gaarenstroom KN, van der Kolk LE, Collée JM, Wevers MR, Ausems MGEM, Van Engelen K, Van De Beek I, Berger LPV, Van Asperen CJ, Gomez Garcia EB, Maas AHEM, Hooning MJ, Van Der Wall E, Van Leeuwen FE, Schagen SB.
    • BJOG. 2023 Jan 30. doi: 10.1111/1471-0528.17415. Epub ahead of print.

    • Integrative Analysis of Germline Rare Variants in Clear and Non-Clear Cell Renal Cell Carcinoma.
    • Han S, Camp SY, Chu H, Collins R, Gillani R, Park J, Bakouny Z, Ricker CA, Reardon B, Moore N, Kofman E, Labaki C, Braun D, Choueiri TK, AlDubayan SH, Van Allen EM.
    • medRxiv [Preprint]. 2023 Jan 19:2023.01.18.23284664. doi: 10.1101/2023.01.18.23284664.

    • Estimating clinical risk in gene regions from population sequencing cohort data.
    • Fife JD, Cassa CA.
    • medRxiv [Preprint]. 2023 Jan 9:2023.01.06.23284281. doi: 10.1101/2023.01.06.23284281.

    • Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
    • Pujade-Lauraine E, Brown J, Barnicle A, Wessen J, Lao-Sirieix P, Criscione SW, du Bois A, Lorusso D, Romero I, Petru E, Yoshida H, Vergote I, Colombo N, Hietanen S, Provansal M, Schmalfeldt B, Pignata S, Martín Lorente C, Berton D, Runnebaum IB, Ray-Coquard I.
    • JCO Precis Oncol. 2023 Jan;7:e2200258. doi: 10.1200/PO.22.00258.

    Related:

    •• Identifier: NCT02477644: Platine, Avastin and OLAparib in 1st Line (PAOLA-1). (ClinicalTrials.gov . Accessed 2023 Jan 30.)

    • Utility of RNA testing in individuals at increased risk for hereditary or familial pancreatic cancer. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Dudley B, Karloski E, Millard C, Carraway C, Hoang L, Karam R, Everett J, Brand R.
    • Fam Cancer. [O-08: Research Categories» Pancreatic cancer-related syndromes.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract

    • Factors Influencing Residual Glandular Breast Tissue after Risk-Reducing Mastectomy in Genetically Predisposed Individuals Detected by MRI Mammography.
    • Dietzel F, Kolberg L, Vesper AS, Hoffmann J, Nestle-Krämling C, Zwiefel K, Friebe V, Sawicki LM, Bruckmann NM, Jannusch K, Morawitz J, Antoch G, Fehm TN, Kirchner J, Mohrmann S.
    • Cancers (Basel). 2023 Jan 29;15(3):829. doi: 10.3390/cancers15030829.

    • Factors Influencing Residual Glandular Breast Tissue after Risk-Reducing Mastectomy in Genetically Predisposed Individuals Detected by MRI Mammography.
    • Dietzel F, Kolberg L, Vesper AS, Hoffmann J, Nestle-Krämling C, Zwiefel K, Friebe V, Sawicki LM, Bruckmann NM, Jannusch K, Morawitz J, Antoch G, Fehm TN, Kirchner J, Mohrmann S.
    • Cancers (Basel). 2023 Jan 29;15(3):829. doi: 10.3390/cancers15030829.

    • Utility of RNA testing in individuals at increased risk for hereditary or familial pancreatic cancer. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Dudley B, Karloski E, Millard C, Carraway C, Hoang L, Karam R, Everett J, Brand R.
    • Fam Cancer. [O-08: Research Categories» Pancreatic cancer-related syndromes.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract